Global Digestive Enzymes Market

Medical feed additives are various types of products used in animal nutrition to improve the nutritional content and quality of feed, or to improve the health and performance of animals. They help improve the nutritional content and quality of feed, resulting in higher productivity and disease prevention. The main types of medical feed additives are antioxidants, antibiotics, probiotics, prebiotics, enzymes, and amino acids. The antioxidants refer to the feed additives that are fed to the animals for nutrition. The different mixtures include supplements, concentrates, premixed feeds, and base mixes. The various classes include typing a, type b, and type c. These are used by different livestock, such as ruminants, poultry, swine, and aquaculture. The medical feed additives research report is one of a series of new reports from The Business Research Company that provides medical feed additives statistics, including medical feed additives industry global market size, regional shares, competitors with medical feed additives share, detailed medical feed additives segments, market trends and opportunities, and any further data you may need to thrive in the medical feed additives industry. This medical feed additives research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global medical feed additives market size will grow from $14.38 billion in 2022 to $15.6 billion in 2023 at a compound annual growth rate (CAGR) of 8.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global medical feed additives market size is expected to grow to $20.75 billion in 2027 at a CAGR of 7.4%. An increase in the prevalence of diseases among animals is driving the growth of the medicated feed additives market. According to estimates from a report by the Animal and Plant Health Agency, a total of 3289 new TB herd incidents were detected in England. A new herd incident is a case of bovine TB that occurs as a result of a herd or individual animal test performed in an officially TB-free (OTF) herd during the study period. Bovine tuberculosis is a chronic disease that usually affects animals such as cattle, but it can affect all mammals, causing illness, coughing, and eventual death. Moreover, according to the reports, the herd incidence rate in England for the 12 months to September 2020 was 9.4. The additives help prevent animals from diseases alongside increasing the nutrition level of the feed, thereby increasing demand for feed additives. The overuse and inappropriate use of antibiotics in medical feed additives impacts the health of individuals consuming animal meat or other related products. Moreover, the health of the animal consuming the feed may also be adversely affected by the antibiotics added to the feed as the excess additive reduces the natural immunity of the animal and increases the susceptibility of the livestock to infections. For instance, in July 2020, the Ministry of Agriculture and Rural Affairs in China, under Announcement No. 194, banned the production of commercial feed with medicated feed additives (excluding traditional Chinese medicine) for growth-promoting purposes. The negative effects of additives on human health caused by overuse of feed additives in animals will restrain the growth of the market. Companies in the medical feed additives market are introducing new feed medicated additives formed as a result of a combination of two or more medicated feed additives. More than 70% of manufacturers are now using more than one feed additive in animal feed to increase the efficiency of the product. For instance, Zoetis, a global health company, got approval for its Cyden and Lincomix combination feed additive from the FDA (Food and Drug Administration) and it is proposed to be used as a medicated feed additive for poultry. Also, the FDA-approved combination of Zoetis’ feed additives ACTOGAIN 45 (ractopamine hydrochloride) and ENGINE (ractopamine hydrochloride) produces more lean muscle and less fat while optimising feed efficiency. The medical feed additives market is regulated by government agencies that lay down regulations to be followed by all manufacturers of veterinary medicines. For instance, the Veterinary Medicines Regulations (VMR) 2013 make provision for the authorization, manufacturing, and classification of veterinary products, including medicated feed additives. Schedule 5 under EU guidelines covers medicated feeding stuff and specified feed additives, which specify guidance to both manufacturers and suppliers of veterinary medicines for incorporating them into animal feed, as well as to veterinary surgeons, animal keepers, and other members involved in the use of veterinary medicines and SFAs(Specified Feed Additives)in animal feeding stuff. In June 2022, Cargill, Inc., a US-based food and agriculture company, acquired DelaconBiotechnik GmbH for an undisclosed amount. The acquisition combines Delacon's innovative know-how and market experience with Cargill's extensive global network and deep expertise in animal nutrition technologies. Phytogenic feed additives are a category that utilizes a variety of herbs, plants, and their extracts, such as essential oils, to enhance livestock and aquaculture performance, promote animal health, and enhance Cargill’s feed additive research capabilities. DelaconBiotechnik GmbH is an Austria-based feed additive company pioneering in plant-based phytogenic additives to improve livestock and aquaculture performance and promote animal health. Major players in the medical feed additives market are Zoetis Inc., Cargill, Incorporated, CHS Inc., Purina Animal Nutrition, Archer Daniels Midland Company, Adisseo France Sas, Alltech Inc., Hipro Animal Nutrition, BASF SE, Biostadt India Limited. North America was the largest region in the medical feed additives market in 2022. Asia-Pacific was the second-largest region in the global medical feed additives market. The regions covered in the global medical feed additives report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the medical feed additives market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, and USA. The medical feed additives market consists of sales of digestibility enhancers, coccidiostats and histomonostats, antimicrobials, and growth hormones. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global medical feed additives market is segmented - 1) By Type: Antioxidants, Antibiotics, Probiotics And Prebiotics, Enzymes, Amino Acids 2) By Livestock: Ruminants, Poultry, Swine, Aquaculture 3) By Mixture Type: Supplements, Concentrates, Premix Feeds, Base Mixes 4) By Class type: Type A, Type B, Type C

Synthetic biology is a field of biological science that involve engineering principles to redesign organisms to give them new abilities. It is possible to think of synthetic biology as the culmination or the prescriptive, deliberate stage of biology. The main product types of synthetic biology are oligonucleotides, enzymes, cloning and assembly kits, xeno-nucleic acids (XNA), and chassis organisms. Oligonucleotides are small single-stranded DNA segments that, when internalized by the cell, can specifically suppress the expression of a single protein. The various technologies include nucleotide synthesis and sequencing, bioinformatics, microfluidics, and genetic engineering that are applied in pharmaceuticals and diagnostics, chemicals, biofuels, bioplastics, and others. The synthetic biology market research report is one of a series of new reports from The Business Research Company that provides synthetic biology market statistics, including synthetic biology industry global market size, regional shares, competitors with a synthetic biology market share, detailed synthetic biology market segments, market trends and opportunities, and any further data you may need to thrive in the synthetic biology industry. This synthetic biology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global synthetic biology market will grow from $13.11 billion in 2022 to $17.07 billion in 2023 at a compound annual growth rate (CAGR) of 30.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global synthetic biology market is expected to grow to $39.12 billion in 2027 at a CAGR of 23.0%. DNA sequencing is important in the development of the synthetic biology in many ways. DNA sequencing finds its use in many synthetic biology applications, therefore the availability of the DNA sequencing technique at low cost drives the production of products based on the applications of synthetic biology. DNA sequencing allows the researchers to determine the DNA sequences in genes and helps a researcher to create a repository of entire genomes. These repositories form the basis for the implementation of synthetic biology applications such as protein expression, directed evolution, and metabolic engineering. According to the Human Genome Research Institute, in 2021,, costs per genome sequenced have decreased from $3 billion to approximately $300 million over the past 17 years and are projected to be gradually lowered by 10 times over the next five years. The bio-safety risks involved in synthetic biology restrains the synthetic biology market. Synthetic biology involves researches on micro-organism to perform the desired function or produce a biological desired substance. Such processes possess health risks such as illness, and allergies in humans as well as environmental risks such as toxicity and risk of new micro-organisms affecting living creatures in the ecosystem. Such potential risks pose as a deterrent to possible innovative research that could be done in certain fields such as combating epidemics such as Ebola and life-threatening diseases such as cancer. The new technological advances in the field of DNA sequencing has enabled the researchers to use DNA to store non-genetic information. With the rise in the demand to store quantum of data, DNA data storage offers a solution where one DNA strand can store about 455 Exabyte of data (455 billion gigabytes). Thus, the concept has received huge investments from the entities in the market. The binary data (data coded in 0O and 1) is converted into DNA strings of four potential base units of unique sequences of A, G, C, T (DNA is made up of four base components: Adenine, Guanine, Cytosine, and Thymine (known as AGCT)). The information coded in DNA lasts for thousands of years when compared to the data in traditional hard drives which gets corrupted or damaged within 30 years. For instance, according to a journal published by Nature Publishing Group, Microsoft and University of Washington researchers stored 35 distinct digital files in DNA—more than 200 megabytes of data and plans to increase future investment to improve the technology. In March 2020, Zymergen, a California-based material innovation company rethinking biology and reimagining the world acquired enEvolv, Inc. for an undisclosed amount. This acquisition speeds Zymergen delivery of high performance and sustainable products to customers and further cements Zymergen leadership position in the bio-manufacturing space. enEvolv, Inc., a next-generation synthetic biology company that has developed an enzyme and strain development platform to harness the power of evolution and create unique, commercial products by engineering the genomes of microbes. Major players in the synthetic biology market are Thermo Fischer Scientific, Genscript, Integrated DNA Technologies, Amyris, Twist Bioscience Corporation, Novozymes, New England Biolabs, Synthetic Genomics, Ginkgo Bioworks, Intrexon, E. I. Du Pont De Nemours and Company, Koninklijke DSM N.V., Codexis, Merck KGaA, Danaher Corporation, EnBiotix, Evonetix, Prokarium, Eurofins Scientific, Origene technologies, Pareto Biotechnologies, Blue heron, Syntrox, ATUM, and DNA2.0. North America was the largest region in the synthetic biology market in 2022. Western Europe was the second largest region in the global synthetic biology market. The regions covered in the global synthetic biology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the synthetic biology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The synthetic biology market includes revenue earned by synthetic compound, technology and related services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global synthetic biology market is segmented - 1) By Technology: Nucleotide Synthesis And Sequencing, Bioinformatics, Microfluidics, Genetic Engineering 2) By Application: Pharmaceuticals And Diagnostics, Chemicals, Biofuels, Bioplastics, Other Applications 3) By Product Type: Oligonucleotides, Enzymes, Cloning and Assembly Kits, Xeno-nucleic Acids (XNA), Chassis Organism

Nutritional feed additives various types of products used in animal nutrition to improve the nutritional content and quality of feed, or to improve the health and performance of animals. They help improve the nutritional content and quality of feed, resulting in higher productivity and disease prevention. The main additive types of nutritional feed additives are antibiotics, vitamins, antioxidants, amino acids, enzymes, mycotoxin detoxifiers, prebiotics, probiotics, flavours and sweeteners, pigments, binders, and minerals. Antibiotics are medications that aid in the treatment of bacterial illnesses. They accomplish this by either killing the bacteria or preventing them from replicating or reproducing. The nutritional feed additives are available in various forms, such as dry, liquid, and other forms that are used on ruminants, poultry, swine, and aquatic livestock. The additives are distributed through direct, indirect channels; hypermarkets and supermarkets; specialty stores, and online retail channels. The nutritional feed additives research report is one of a series of new reports from The Business Research Company that provides nutritional feed additives statistics, including nutritional feed additives industry global market size, regional shares, competitors with nutritional feed additives share, detailed nutritional feed additives segments, market trends and opportunities, and any further data you may need to thrive in the nutritional feed additives industry. This nutritional feed additives research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global nutritional feed additives market size will grow from $3.89 billion in 2022 to $4.19 billion in 2023 at a compound annual growth rate (CAGR) of 7.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global nutritional feed additives market size is expected to grow to $5.41 billion in 2027 at a CAGR of 6.6%. The rise in consumption of meat products is one of the driving factors for the nutrition feed additives market. Due to high meat consumption, the concern for high-quality meat is also increasing. Thus, to deliver high-quality meat, add-on nutrition feed additives are fed to the animals so that they have good digestion to build on more muscle and weight. This increases the yield and productivity and, hence, the demand for nutritional feed additives. Currently, meat and poultry consumption in the US is more than 100 billion pounds every year. The stringent regulations act as one of the major restraining factors for the nutrition feed additives market. There are many mandatory documents, required to be approved before approving the nutritional feed, which delays the approval process. Therefore, the product launch and expansion of companies in new regional markets will be delayed. For instance, China's AQSIQ (Administration for Quality Supervision and Inspection and Quarantine) issued 2 reports for the nutrition feed additive companies to get their products registered and approved by the concerned Chinese authorities before selling them in the Chinese market. The report also made it compulsory for all the exporters to have a licence to sell their nutrition feed additive products in the Chinese market, which delays the nutritional feed additives from reaching the stores. Feed additives manufacturers are investing in the R&D of organic feed additives as there is a growing demand for organic and natural feed products in the nutritional feed additives market. When compared to synthetic nutrition feed additives, organic feed additives have fewer side effects and also improve yield. Therefore, poultry farmers are switching to herbal nutrition feed additives. For instance, Agpulse Organics has come up with its herbal animal feed additive 'Govahnika-Biosheera', which is fed to cattle to increase milk productivity while maintaining the health of cattle and quality of milk. In September 2020, Adisseo acquired Framelco G for an undisclosed amount. With this acquisition, the company will enhance the growth of specialties to become the world leader in the field of specialty feed ingredients in animal nutrition. Framelco G is a family-owned multinational company that develops and manufactures feed additives and drinking water solutions for livestock production. Major players in the nutritional feed additives market are BASF SE, Cargill, Archer Daniels Midland Company, Evonik Industries AG, Nutreco N.V., Kemin Industries Inc., Adisseo, Alltech, Phibro Animal Health Corporation, and DowDuPont. North America was the largest region in the nutritional feed additives market in 2022. Asia-Pacific was the second-largest region in the global nutritional feed additives market. The regions covered in the global nutritional feed additives market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the nutritional feed additives market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The nutritional feed additives market consists of sales of digestibility enhancers, coccidiostats and histomonostats, antimicrobials, and growth hormones. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global nutritional feed additives market is segmented - 1) By Distribution Channel: Direct, Indirect, Hypermarket/Supermarket, Specialty Stores, Online Retail 2) By Livestock: Ruminants, Poultry, Swine, Aquatic 3) By Additive Type: Antibiotics, Vitamins, Antioxidants, Amino Acids, Enzymes, Mycotoxin Detoxifiers, Prebiotics, Probiotics, Flavors And Sweeteners, Pigments, Binders, Minerals 4) By Form: Dry, Liquid, Other Forms

Specialty enzymes refer to proteins that have the ability to operate as very selective biocatalysts to speed up reactions and create the required target molecule in medicines. Specialty enzymes are important in a wide range of treatment modalities and applications, most frequently for modification but also to lower viscosity and hence enhance processability and to connect and detach cells, which increases productivity. The main types of specialty enzymes are carbohydrases, proteases, lipases, polymerases & nucleases, oxidases and hydratases, and others. Any of a class of enzymes (such as amylase) that promotes carbohydrate breakdown or synthesis is referred to as a carbohydrase (such as a disaccharide). The different sources include microorganisms, animals, and plants and are used in pharmaceutical, diagnostics, research and biotechnology, food and beverage, animal nutrition, and others. The specialty enzymes market research report is one of a series of new reports from The Business Research Company that provides specialty enzymes market statistics, including specialty enzymes industry global market size, regional shares, competitors with a specialty enzymes market share, detailed specialty enzymes market segments, market trends and opportunities, and any further data you may need to thrive in the specialty enzymes industry. This specialty enzymes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global specialty enzymes market grew from $5.57 billion in 2022 to $5.97 billion in 2023 at a compound annual growth rate (CAGR) of 7.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The specialty enzymes market is expected to grow from $7.8 billion in 2027 at a CAGR of 6.9%. Growing investment in biotechnology research and development is expected to boost market growth during the forecast period. Specialty enzymes are widely used in biotech research and development, particularly in molecular biology. The increasing investment and an increase in the number of companies conducting biotechnology research and development will in turn increase the number of biotech researchers. For instance, in April 2021, according to a report published by the Congressional Budget Office, a US-based government agency that provides budget and economic information, pharmaceutical companies will have invested $83 billion on research and development activities around the world. According to the Assobiotec publication BioInItaly 2020, healthcare is involved in 49% of the over 700 biotech firms headquartered in Italy. As a result of increased investment in biotech R&D, the growing number of biotech research companies is expected to boost the specialty enzymes market. Ethical and societal issues are factors that will slow down the market's growth during the forecast period. The clashing public opinions on these issues will determine the acceptability of new industrial biotechnology products. In 2019, a published article stated that there are five societal and ethical themes concerning industrial biotechnology, namely sustainability, naturalness, risk management, innovation trajectories, and economic justice. Many critics state that the factor affecting economic justice is that the applications of industrial biotechnology lead to the concentration of knowledge and power in the hands of a few companies. Thus, societal and ethical issues are expected to impact market growth. Technological advancements show opportunities for the production of enzyme products more efficiently. Challenges such as complexity in maintaining pH, the operational high temperature of specialty enzymes, and the significant cost of maintenance of specialty enzyme products pave the way for technological advancements. For instance, in February 2020, DuPont Nutrition Biosciences ApS, a Denmark based company specialising in the development, manufacturing, and sale of ingredients for food and beverages, enzymes, and bio-based products, launched the POWERBake enzyme based on its emulsification technology. The enzymes give bakeries and improvement centers a special emulsification solution that satisfies consumer expectations for cleaner labelling while maintaining the flavour and quality of white breads and buns. In May 2021, BRAIN AG, a Germany-based industrial biotechnology company that identifies and develops innovative solutions and products for use in the chemistry, cosmetics, and food industries, paid $ 5.51 million (GBP 3.9 million) for additional shares in Biocatalysts Ltd.The acquisition further strengthens BRAIN’s BioIndustrial segment and widens commercial opportunities with Biocatalyst's portfolio and technology, including access to BRAIN’s unique BioArchive and Biocatalyst’s MetXtra metagenomic library. Biocatalysts Ltd. is a UK-based manufacturer of specialty enzymes that focuses on the use of technology to develop novel specialty enzymes cost-effectively. Major players in the specialty enzymes market are BASF SE, Novozymes A/S, Roche Holding AG, Codexis Inc., Specialty Enzymes & Probiotics, Advanced Enzyme Technologies Ltd., BBI Solutions, E. I. du Pont de Nemours and Company, Sanofi, and Amano Enzyme Inc. North America will be the largest region in the viral specialty enzymes market in 2022. The Middle East is expected to be the fastest growing region in the global specialty enzymes market during the forecast period. The regions covered in the global specialty enzymes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The specialty enzymes market consists of sales of acylases, hydratases, humulin oxidase, and lyases. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The countries covered in the specialty enzymes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global specialty enzymes market is segmented - 1) By Type: Carbohydrases, Proteases, Lipases, Polymerases & Nucleases, Oxidase & Hydratases, Other Types 2) By Source: Microorganisms, Animals, Plants 3) By Application: Pharmaceutical, Diagnostics, Research & Biotechnology, Food & Beverage, Animal Nutrition, Other Applications

Animal growth promoters and performance enhancers refer to the substances that are added to feeds as supplements or injections to increase feed utilization and growth in farm animals, as well as veterinary medicinal products that are administered to healthy animals in order to favourably influence the yield, quality, and/or growth of animal products. The main types of animal growth promoters and performance enhancers are antibiotic growth promoters and non-antibiotic growth promoters. Antibiotic growth promoters refer to the promoters that will enhance the health of the animal and increase productivity. These include natural chemicals such as microbial products, prebiotics, and probiotics; yeast products; enzymes and herbs; oils; and spices. The different types of animals that use animal growth promoters and performance enhancers include poultry, swine, livestock, aquaculture, and other animals. The animal growth promoters and performance enhancers research report is one of a series of new reports from The Business Research Company that provides animal growth promoters and performance enhancers statistics, including animal growth promoters and performance enhancers industry global market size, regional shares, competitors with animal growth promoters and performance enhancers share, detailed animal growth promoters and performance enhancers segments, market trends and opportunities, and any further data you may need to thrive in the animal growth promoters and performance enhancers industry. This animal growth promoters and performance enhancers research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global animal growth promoters and performance enhancers market size will grow from $13.73 billion in 2022 to $14.65 billion in 2023 at a compound annual growth rate (CAGR) of 6.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global animal growth promoters and performance enhancers market size is expected to grow to $18.92 billion in 2027 at a CAGR of 6.6%. The growing demand for meat is a significant factor that will drive the market for animal growth promoters and performance enhancers. Animal growth promoters make the animal accumulate fat and weight, resulting in more meat production and a more expensive animal. Meat is a major protein source for many people around the world. According to a study by FAO, the production of meat has doubled in the last 30 years and increased four-fold since the mid-1960s. The production and consumption of meat are expected to continue to grow. By 2050, global meat consumption is projected to reach between 460 million and 570 million tons. This is expected to drive the animal growth promoters and performance enhancers market. Strict rules set by the US and European governments on the use of animal growth promoters and performance enhancers are restricting the animal growth promoter and performance enhancers market. For instance, Zoetis, the largest producer of animal medicines, is banned from selling antibiotics that promote faster growth in animals in the US and Europe. The US FDA has implemented a regulation that bans the use of antibiotics as feed supplements to help livestock and poultry grow faster. These regulations are expected to negatively impact the growth of the market. Companies in the market are increasingly investing in phytogenics for higher efficiency of growth promoters through natural means. Phytogenics, sometimes also referred to as botanicals or phytobiotics, are plant-based feed additives utilised in animal nutrition. They are derived from herbs, spices, and extracts. Phytochemicals can be used in solid, dried, and ground form or as extracts, and can also be classified as essential oils and oleoresins depending on the process used to derive the active ingredients. The use of phytogenics promotes increased feed intake, improved gut function, prevention of diarrhea, and antimicrobial and antioxidative effects in livestock. Companies such as Delacon, Cargill, and BIOMIN have invested in phytogenics. In June 2020, Elanco acquired Bayer Animal Health for $7.6 billion. This acquisition is expected to help Elanco expand its product profile and reach for medicines for pets and livestock. Bayer Animal Health is a division of Bayer HealthCare. Major players in the animal growth promoters and performance enhancers market are Merck Animal Health, Cargill, Royal DSM N.V., Vetoquinol S.A., Bupo Animal Health, Elanco Animal Health Inc., Alltech, Bayer Animal Health, Zoetis, and Bioniche Life Sciences. North America was the largest region in the animal growth promoters and performance enhancers market in 2022. Asia-Pacific was the second-largest region in the global animal growth promoters and performance enhancers market. The regions covered in the global animal growth promoters and performance enhancers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the animal growth promoters and performance enhancers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The animal growth promoters and performance enhancers market consists of sales of growth hormone medications, anabolic implants, bovine somatotropin, ß-agonists and probiotics. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global animal growth promoters and performance enhancers market is segmented - 1) By Type: Antibiotic Growth Promoters, Non-Antibiotic Growth Promoters 2) By Animal Type: Poultry, Swine, Livestock, Aquaculture, Other Animals 3) By Nature of Chemicals: Microbial Products, Prebiotics And Probiotics, Yeast Products, Enzymes/Herbs, Oils And Spices

Diagnostic enzymes refer to the enzymes that are employed directly or as part of an assay system to determine the presence or absence of a variety of compounds, and they are used to detect, diagnose, or predict the development of disease conditions. These enzymes are used in diagnosis because of their substrate selectivity and quantified activity when other proteins are present. The main types of products in diagnostic enzymes are carbohydrates, polymerases, nucleases, proteases, and others. Any of a class of enzymes (such as amylase) that promotes carbohydrate breakdown or synthesis is referred to as a carbohydrase (such as a disaccharide). The different sources include animals, microorganisms, and plants and are used in biocatalysts, diagnostics, pharmaceuticals, research, and biotechnology. The diagnostic enzymes market research report is one of a series of new reports from The Business Research Company that provides diagnostic enzymes market statistics, including global market size, regional shares, competitors with a diagnostic enzymes market share, detailed diagnostic enzymes market segments, market trends and opportunities, and any further data you may need to thrive in the diagnostic enzymes industry. This diagnostic enzymes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global diagnostic enzymes market grew from $3.8 billion in 2022 to $4.02 billion in 2023 at a compound annual growth rate (CAGR) of 5.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The diagnostic enzymes market is expected to grow from $5.1 billion in 2027 at a CAGR of 6.1%. The rise in the geriatric population, which increases the patient pool for the diagnosis of chronic diseases, contributed to the growth of the diagnostic enzymes market. The proportion of people above the age of 65 increased globally, and age-related chronic ailments also increased. For example, the percentage of seniors is expected to grow from 28% in 2019 to 38% by 2050 in Japan. The increase in the ageing population has increased the patient pool of many chronic diseases such as rheumatoid arthritis, hypertension, diabetes, and cancer. People suffering from these diseases are expected to be more vulnerable to chronic diseases, thus significantly influencing market growth during this period. According to the World Population Ageing report, there were 727 million people over the age of 65 in 2020, accounting for 9.3% of the global population, and this figure is expected to rise to around 16.0% by 2050.According to the World Health Organization report for 2021, approximately 10 million cancer-related deaths occurred in 2020. Thus, the rise in the geriatric population increases the number of patients for the diagnosis of chronic diseases, which, in turn, drives the diagnostic enzymes market. The high sensitivity of enzymes to temperature and pH levels is expected to limit the diagnostic enzymes market. Enzymes need to be stored at optimum temperatures and are generally stored at -20 degrees Celsius. According to the Worthington Biochemical Corporation, variations in the reaction by one or two degrees in temperature may have a change of 10 to 20% in the result. In enzymatic reactions, this is complicated as enzymes are adversely affected by high temperatures, and are expected to be deactivated at even moderate temperatures. Enzymes are affected by changes in pH, as pH is also a factor in the stability of the enzymes. The changes in temperature and pH levels may decrease the efficiency of the diagnostic enzymes, which, in turn, hampers the growth of the diagnostic enzymes market. The use of machine learning and artificial intelligence is gradually gaining popularity in the enzyme diagnostic market. Artificial intelligence (AI) is the simulation of human intelligence in machines and is programmed to display their natural intelligence. Machine learning is a part of AI. Machine learning and AI help companies in the enzyme diagnostic market to conduct a detailed analysis of all relevant data, provide insights into the function of enzymes, and allow physicians to understand the key determinants of the relationship between protein structure, function, and evolution, in terms of the catalysis of the reaction steps of an enzyme. For instance, companies such as BioMarker have invested in AI and machine learning for enzyme diagnostics. In June 2020, Codexis, Inc., a US-based protein engineering company and developer of high-performance enzymes, and Alphazyme LLC., a US-based company in the development and manufacture of nucleic acid metabolising enzymes, announced a co-marketing enzyme supply collaboration agreement for the production and co-marketing of enzymes for life science applications, including diagnostics. This collaboration is expected to leverage the experience and industry knowledge of Alphazyme to accelerate the market introduction of Codexis’ portfolio of high-performing life science and diagnostic enzymes while providing Alphazyme with exclusive manufacturing and co-marketing rights to CodeEvolver-improved enzymes. This partnership will allow both companies to jointly promote and sell these enzymes to innovators in life science and diagnostic markets. Major players in the diagnostic enzymes market are Genzyme, Roche, Codexis, Aldevron, Kaneka Eurogentec, Vigene Biosciences, Amano Enzymes, Advanced Enzymes Technologies, Thermo Fisher Scientific, and EKF Diagnostic. North America was the largest region in the enzymes market in 2022. The Middle East is expected to be the fastest-growing region in the global diagnostic enzyme market during the forecast period. The regions covered in the global diagnostic enzymes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the diagnostic enzymes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The diagnostic enzymes market consists of sales of acid phosphatase, alanine aminotransferase, cholinesterase, and aspartate aminotransferase. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global diagnostic enzyme market is segmented - 1) By Product Type: Carbohydrases, Polymerases And Nucleases, Protease, and Other Product Types 2) By Source: Animals, Microorganisms, and Plants 3) By Application: Biocatalysts, Diagnostics, Pharmaceuticals, Research, and Biotechnology

Enzyme refers to a protein that almost usually serves as a biological catalyst. It accelerates a certain chemical reaction in the cell. It is a substance that serves as a catalyst in living things, controlling the speed at which chemical processes take place without undergoing any changes. The main product types of enzymes are asparginase, lipase, protease, nattokinase, chitinase, serratiopeptidase, collagenase, ligase, and others. A protease is an enzyme that catalyzes proteolysis, which breaks proteins down into smaller polypeptides or single amino acids and promotes the formation of new protein products. The enzymes are used for the treatment of leukemia, stomach disorders, antitumor, skin ulcers, gauche disease, Fabry disease, and others and are used by drug manufacturers, hospitals, private clinics, and research laboratories. The enzymes market research report is one of a series of new reports from The Business Research Company that provides enzymes market statistics, including enzymes industry global market size, regional shares, competitors with an enzymes market share, detailed enzymes market segments, market trends, and opportunities, and any further data you may need to thrive in the enzymes industry. This enzymes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global enzymes market grew from $10.25 billion in 2022 to $11.63 billion in 2023 at a compound annual growth rate (CAGR) of 13.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The enzymes market is expected to grow from $19.73 billion in 2027 at a CAGR of 14.1%. The growing prevalence of cancer requiring drug-metabolizing enzymes (DMEs) for chemotherapy is expected to drive the growth of the enzyme market in the coming years. The activation of enzymes in the human body help destroy the cancer cells and breaks down the tumor. The expression and function of drug-metabolizing enzymes (DMEs) in cancer patients' tumor tissues and metabolic organs is therefore essential and help patients for whom reaction to anticancer drugs and response to chemotherapy is low. According to the World Health Organization (WHO), 10 million deaths occurred in 2020 due to cancer and about 70% of deaths from cancer occur in low- and middle-income countries. Therefore, the increasing prevalence of cancer that can be cured using therapeutic enzymes is predicted to drive the growth of the enzyme market. The development of new approaches to treat cancer using enzymes is a key trend gaining popularity in the enzymes market. Major universities and companies are investing in research focusing on evolving new solutions in enzyme therapies for cancer treatment. For example, in August 2020, scientists from McGill University and Osaka University in Japan were able to unlock the behavior of an enzyme involved in the spread of cancer cells by using the CMCF beamline at the Canadian Light Source (CLS) at the University of Saskatchewan. In May 2020, AbbVie Inc., an America-based biopharmaceutical company acquired Allergan plc for $63 billion. This acquisition significantly expands and diversifies AbbVie's revenue base and complements existing leadership positions in Immunology, with Humira and recently launched Skyrizi and Rinvoq, and Hematologic Oncology, with Imbruvica and Venclexta. Allergan plc is an Ireland-based pharmaceutical company engaged in the research, development, and manufacture of pharmaceutical and enzyme-based therapeutic products. Major players in the enzymes market are Sanofi, AbbVie Inc., Alexion Pharmaceuticals Inc, Horizon Pharma, Allergan plc, Pfizer Inc., Vivus, Digestive Care, Leadiant Biosciences, Roche Holdings AG and Codexis Inc. North America was the largest region in the enzymes market in 2022. The regions covered in the enzymes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the enzymes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The enzyme market consists of sales of oxidoreductases, transferases, and hydrolases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products. The global enzyme market is segmented - 1) By Product Type: Asparginase, Lipase, Protease, Nattokinase, Chitinase, Serratiopeptidase, Collagenase, Ligase, Other Products 2) By Application: Leukemia, Stomach Disorders, Antitumor, Skin Ulcers, Gaucher Disease, Fabry Disease, Other Applications 3) By End User: Drug Manufacturers, Hospitals, Private Clinics, Research Laboratories

Epigenetics is a change in gene activity transmitted to younger cells without modifying the DNA sequence. Epigenetic processes are natural and necessary for many organisms to work, but unusual occurrences can cause disorders, such as various types of cancer, reproductive illnesses, and cardiovascular illnesses. Epigenetics is used detect a type of cancers earlier. The main products used in epigenetics market are reagents, enzymes, instruments and kits. Reagents are compounds or substances that are used for chemical analysis or epigenetic testing. DNA methylation, histone methylation, histone acetylation, large noncoding RNA, microRNA modification and chromatin structures are the technologies used in epigenetics. The application included oncology, metabolic diseases, developmental biology, immunology, cardiovascular diseases and other applications. These epigenetics are used by academic and research institutes, pharmaceutical, and biotechnology companies, contract research organizations and other end users. The epigenetics market research report is one of a series of new reports from The Business Research Company that provides epigenetics market statistics, including epigenetics industry global market size, regional shares, competitors with an epigenetics market share, detailed epigenetics market segments, market trends and opportunities, and any further data you may need to thrive in the epigenetics industry. This epigenetics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global epigenetics market size grew from $7.38 billion in 2022 to $8.85 billion in 2023 at a compound annual growth rate (CAGR) of 20.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The epigenetics market size is expected to grow to $18.21 billion in 2027 at a CAGR of 19.8%. The growing prevalence of cancer and other diseases is significantly driving the growth of the epigenetics market. The rising prevalence of diseases increases the demand for epigenetics. According to the European Commission's Joint Research Centre from Ispra, the number of new cancer cases in the European Union (EU) and European Free Trade Association (EFTA) countries will rise by 21.4%, from 2.8 million in 2020 to 3.4 million in 2040. Furthermore, according to the Centers for Disease Control and Prevention (CDC), approximately 659,000 people in the United States die of heart disease each year. The increasing prevalence of cancer and other diseases requires testing and knowing the modifications that happened in the genes, which will invariably increase the usage and demand of epigenetics. Thus, the growing prevalence of cancer and other diseases drives the epigenetics market in the coming years. Technological advancement is the key trend in the epigenetics market. The key players in the epigenetics sector are focusing on developing various technologically advanced products and services to strengthen their position in the market. For instance, in May 2021, Givaudan Active Beauty, a Switzerland-based company specialising in fragrance, beauty, taste and wellbeing, launched Chronoglow. Chronoglow is a skin-care-beneficial active component created by green fractionation and supported by artificial intelligence (AI) that can replicate natural epigenetic mechanisms. Chronoglow is a natural skin remedy made from Haberlea rhodopensis, often known as the resurrection plant, which can improve the skin's luminosity and reverse the signs of aging. In December 2020, Exact Sciences, a US-based molecular diagnostic company, acquired Base Genomics for $140 million. As a result of this acquisition, Exact Sciences aims to create a multi-cancer early detection blood test. This acquisition also aids in the acceleration of clinical and commercial development. Base Genomics is a UK-based epigenetics company working on designing a blood test for minimal residual disease and early-stage cancer. Major players in the epigenetics market are Illumina, Thermo Fisher Scientific, Merck Millipore, Abcam, Active Motif, Bio-Rad, New England Biolabs, Agilent, Qiagen, Zymo Research, Perkinelmer, Diagenode, Hoffmann-La Roche Ltd., Eisai Co Ltd and Novartis AG. North America was the largest region in the epigenetics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epigenetics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the epigenetics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The epigenetics market includes revenues earned by entities methylation, acetylation, phosphorylation, ubiquitylation, and sumolyation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global epigenetics market is segmented - 1) By Product: Reagents, Enzymes, Instruments, Kits 2) By Technology: DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification, Chromatin Structures 3) By Application: Oncology, Metabolic Diseases, Developmental Biology, Immunology, Cardiovascular Diseases, Other Applications 4) By End-User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Contract Research Organisations, Other End Users